We have now performed a large study analyzing metastases from different sites, while restaining metastases and primary tumors side-by-side with optimal current immunohistochemical methods for ERα, PR and HER2 on full sections to asses the conversion rate of ERα, PR and HER2 status in distant metastases compared to the primary breast carcinomas. The gene discussed is PGR; the disease is breast carcinoma.